Mylan announced that the FDA has approved its abbreviated new drug application (ANDA) for Candesartan Cilexetil and Hydrochlorothiazide Tablets, the generic version of AstraZeneca‘s Atacand HCT.

Atacand HCT is indicated for the treatment of hypertension and may be substituted for titrated components, but is not for initial therapy.  It is a combination of candesartan cilexetil, an angiotensin II receptor blocker, and hydrochlorothiazide, a diuretic.

Candesartan and Hydrochlorothiazide Tablets are available in 16mg/12.5mg, 32mg/12.5mg, and 32mg/25mg dosage strengths.  Mylan is shipping all strengths of this product immediately.

For more information call (800) RX-MYLAN or visit